Ovarian and tubal cancer in Denmark: an update on incidence and survival

Acta Obstetricia et Gynecologica Scandinavica

Volumn 95, Issue 10, 2016, Pages 1181-1189

  Gottschau, Mathilde ^a   Mellemkjaer, Lene ^a   Hannibal, Charlotte G ^a   Kjaer, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Epidemiology; fallopian tube cancer; incidence; ovarian cancer; survival

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; DANISH CITIZEN; DENMARK; FEMALE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; NORWAY; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL RATE; SWEDEN; UTERINE TUBE CARCINOMA;

EID: 84988423399     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12948     Document Type: Article

References (33)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase no.11. Lyon: International Agency for Research on Cancer, 2013. Available online at: http://globocan.iarc.fr (accessed March 16, 2016).
2. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55:3–23.
3. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer. 2003;97:2631–42.
4. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. Cancer J Clin. 2011;61:183–203.
5. Kalampokas E, Kalampokas T, Tourountous I. Primary fallopian tube carcinoma. Eur J Obstet Gynecol Reprod Biol. 2013;169:155–61.
6. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–43.
7. Vang R, Shih I, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62:44–58.
8. Klint A, Tryggvadóttir L, Bray F, Gislum M, Hakulinen T, Storm HH, et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:632–43.
9. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trend in incidence and mortality in 28 countries, 1953–2000. Int J Cancer. 2012;113:977–90.
10. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol. 2012;127:75–82.
11. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2014;2025:1–34.
12. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry – history, content, quality and use. Dan Med Bull. 1997;44:535–9.
13. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl):42–5.
14. Engholm G, Ferlay J, Christensen N, Kejs A, Johannesen T, Khan S, et al. NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries, version 7.2 (16.12.2015). Association of the Nordic Cancer Registries. Danish Cancer Society. Available online at: http://www.ancr.nu (accessed April 8, 2016).
15. National Cancer Intelligence Network. Overview of ovarian cancer in England: incidence, mortality and survival. 2012. Available online at: http://www.ncin.org.uk/publications (accessed January 15, 2016).
16. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev. 2009;18:132–9.
17. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420–32.
18. Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953–97. Int J Cancer. 2003;104:643–5.
19. Schüler S, Ponnath M, Engel J, Ortmann O. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet. 2013;287:1187–204.
20. Lidegaard Ø, Schiødt A, Poulsen E. P-piller. Generelle forhold [Oral contraceptives. General aspects] (in Danish). Ugeskr Laeger. 2001;163:4544–6.
21. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385:1835–42.
22. von Euler-Chelpin M. Breast cancer incidence and use of hormone therapy in Denmark 1978–2007. Cancer Causes Control. 2011;22:181–7.
23. Roussouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
24. Yang HP, Anderson WF, Rosenberg PS, Trabert B, Gierach GL, Wentzensen N, et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol. 2013;31:2146–51.
25. Lowe KA, Chia VM, Taylor A, O'Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130:107–14.
26. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377:127–38.
27. The Danish National Board of Health. Specialeplanlægning og lands- og landsdelsfunktioner i sygehusvæsenet [Specialty planning and country-region functions in the health care] (in Danish). 2001.
28. Marx CI, Møller C, Bendixen A, Kehlet H, Ottesen BS. Ovariekræft i Danmark. Status for den kirurgiske indsats [Ovarian cancer in Denmark. Status on the surgical intervention] (in Danish). Ugeskr Laeger. 2006;168:1537–40.
29. Høgdall CK, Petri AL. Årsrapport 2005 – Dansk Gynækologisk Cancer Database [Annual report 2005 – Danish Gynecologic Cancer Database] (in Danish). Available online at: http://www.dgcg.dk/images/DGCD__aarsrapport_net05.pdf (accessed January 15, 2016).
30. Høgdall CK, Nielsen MLS, Taaning L. Årsrapport 2008 – Dansk Gynækologisk Cancer Database [Annual report 2008 – Danish Gynecologic Cancer Database] (in Danish). Available online at: http://www.dgcg.dk/images/DGCD_Aarsrapport_net08.pdf (accessed January 15, 2016).
31. Høgdall CK, Taaning L, Nielsen MLS. Årsrapport 2011 – Dansk Gynækologisk Cancer Database [Annual report 2011 – Danish Gynecologic Cancer Database] (in Danish). Available online at: http://www.dgcg.dk/images/DGCD%20rsrapport%202011.pdf (accessed January 15, 2016).
32. Dansk Gynækologisk Cancer Gruppe. Retningslinier for visitation, diagnostik og kontrol af epitelial ovarie-, tuba- og primær peritonealcancer samt borderline tumorer [Guidelines for visitation, diagnosis and control of epithelial ovarian cancer, primary fallopian tube carcinoma, primary peritoneal cancer and borderline tumors] (in Danish). Available online at: http://dgcg.dk/images/retningslinier/Retningslinier_ovariecancer_april_2014.pdf (accessed April 8, 2016).
33. Hannibal CG, Cortes R, Engholm G, Kjaer SK. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978–2002. Acta Obstet Gynecol Scand. 2008;87:1353–60.